Technology group OMESTI Berhad (OMESTI) is further expanding its portfolio of healthcare services with the formation of two strategic joint venture companies (JVC), leveraging the Group’s digitisation track record.
A JVC has been established with Medical Innovation Ventures Sdn Bhd (Mediven®) for the purpose of setting up and operating a diagnostics and test laboratory, for conducting, amongst others, PCR (Polymerase Chain Reaction) testing used in the definitive detection of coronavirus infections. The first laboratory, to be located in Penang, will be operated on behalf of the JVC by Mediven® technicians, and backed by Mediven’s comprehensive diagnostics technology and expertise.
The second JVC has been established with Tree Med Sdn Bhd (Tree Med/TMSB), a company which is engaged in the supply of medical and laboratory equipment. The JVC is being formed for the purpose of collaboration in healthcare projects which includes amongst others participating and bidding in tenders issued by the healthcare sector. The delivery of such projects will utilise resources pooled from both JVC parties.
Gerard Monteiro, Executive Director of OMESTI Berhad, said, “These new joint ventures represent an important initiative on our part to expand our healthcare portfolio in line with our overall growth strategy. The JVCs will be able to leverage the considerable expertise and resources of Mediven® and Tree Med, combined with our own technology expertise and increase our footprint in the healthcare sector.”
These latest initiatives follow on from the earlier investment of RM15.8 million by OMESTI in the Bemed Group of companies, which added trading and retail sale of pharmaceutical products, orthopaedic and medical goods, perfumery products, cosmetics and toiletries to its portfolio. These activities are in addition to the sales and distribution of COVID-19 vaccines and Rapid Test-Kits already being handled by OMESTI.
OMESTI’s technology expertise and track record will lead to the full digitisation of its healthcare operations, putting the patient and consumer at the heart of the ecosystem. This digital ecosystem, which will be rolled out in phases, will span the entire medical requirements chain with services ranging from e-consultations with medical professionals to diagnosis, through to prescription issue and fulfilment, follow-up consultation and purchase of general medical supplies via the Group’s digital pharmacy portal.